At Brooklyn ImmunoTherapeutics, we are inspired by the history of Brooklyn and the pivotal role the Brooklyn Army Terminal played as a supply hub for essential materials during the Second World War. For decades, people from around the world traveled to America and settled in Brooklyn, making it one of the most diverse Boroughs in New York. Brooklyn used this diversity to bring together and create a distinct identity, exemplified by its motto which translates as Unity Makes Strength. This strength in diversity is also exemplified in IRX-2, a unique biologic which uses a unique combination of diverse cytokines, including IL-2, to restore immune function to fight cancer. Today, from our location in the Brooklyn Army Terminal, our goal is to develop and supply a powerful new therapeutic option in the global battle against cancer.
Brooklyn ImmunoTherapeutics is committed to scientific rigor, and research integrity in all that we do. We go where the science leads us.
We value diversity of experience, skills and viewpoint combined with a willingness to contribute new perspectives in the development of IRX-2 across multiple indications.
We are focused in all we do in advancing the science and clinical application of cytokine-based therapy for the benefit of patients living with cancer.